Labeled for this condition
Medicines for lung cancer
55 medicines have an FDA label indicated for lung cancer; 10 are listed from generic labelers and 0 have a presentation in shortage now (FDA files, October 8, 2026).
Which medicines are labeled for lung cancer?
Each label names the condition in its indications; the record shows the label's words. A list of labeled medicines is not a treatment plan.
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Pemetrexed | Pemrydi, Alimta, Axtle | 15 labelers | n/a | No | A presentation being discontinued | 5 |
| Docetaxel | Beizray, Docivyx | 14 labelers | n/a | Yes | A presentation being discontinued | 7 |
| Paclitaxel | Abraxane | 19 labelers | n/a | Yes | No current entry | 2 |
| Gemcitabine | Avgemsi, Inlexzo | 10 labelers | n/a | No | No current entry | 5 |
| Erlotinib | none listed | 10 labelers | n/a | No | No current entry | 0 |
| Etoposide | Avopef, Vepesid, Etopophos | 6 labelers | n/a | Yes | No current entry | 1 |
| Bevacizumab | Zirabev, Avastin, Vegzelma | none listed | n/a | No | No current entry | 3 |
| Topotecan | Hycamtin | 4 labelers | n/a | Yes | No current entry | 1 |
| Afatinib | Gilotrif | 1 labeler | n/a | No | No current entry | 0 |
| Selpercatinib | Retevmo | none listed | n/a | No | No current entry | 0 |
| Crizotinib | Xalkori | none listed | n/a | No | No current entry | 0 |
| Durvalumab | Imfinzi | none listed | n/a | No | No current entry | 1 |
| Gefitinib | Iressa | 4 labelers | n/a | No | No current entry | 0 |
| Trametinib | Mekinist | none listed | n/a | No | No current entry | 0 |
| Amivantamab and hyaluronidase | Rybrevant | none listed | n/a | No | No current entry | 0 |
| Brigatinib | Alunbrig | none listed | n/a | No | No current entry | 0 |
| Capmatinib | Tabrecta | none listed | n/a | No | No current entry | 0 |
| Dabrafenib | Tafinlar | none listed | n/a | No | No current entry | 0 |
| Nivolumab | Opdivo | none listed | n/a | No | No current entry | 1 |
| Dacomitinib | Vizimpro | none listed | n/a | No | A presentation being discontinued | 0 |
| Entrectinib | Rozlytrek | none listed | n/a | No | No current entry | 0 |
| Lorlatinib | Lorbrena | none listed | n/a | No | A presentation being discontinued | 0 |
| Sotorasib | Lumakras | none listed | n/a | No | No current entry | 0 |
| Alectinib | Alecensa | none listed | n/a | No | No current entry | 0 |
| Atezolizumab | Tecentriq | none listed | n/a | No | No current entry | 1 |
| Berahyaluronidase alfa and pembrolizumab | Keytruda | none listed | n/a | No | No current entry | 0 |
| Bevacizumab-maly | Alymsys | none listed | n/a | No | No current entry | 0 |
| Cemiplimab | Libtayo | none listed | n/a | No | No current entry | 1 |
| Ceritinib | Zykadia | none listed | n/a | No | No current entry | 0 |
| Ensartinib | Ensacove | none listed | n/a | No | No current entry | 0 |
| Hyaluronidase and nivolumab | Opdivo | none listed | n/a | No | No current entry | 0 |
| Ipilimumab | Yervoy | none listed | n/a | No | No current entry | 0 |
| Lazertinib | Lazcluze | none listed | n/a | No | No current entry | 0 |
| Ramucirumab | Cyramza | none listed | n/a | No | No current entry | 1 |
| Repotrectinib | Augtyro | none listed | n/a | No | No current entry | 0 |
| Tarlatamab-dlle | Imdelltra | none listed | n/a | Yes | No current entry | 0 |
| Telisotuzumab vedotin | Emrelis | none listed | n/a | No | No current entry | 0 |
| Tremelimumab | Imjudo | none listed | n/a | No | No current entry | 0 |
| Vinorelbine | none listed | 2 labelers | n/a | Yes | No current entry | 0 |
| Zenocutuzumab | Bizengri | none listed | n/a | Yes | No current entry | 0 |
| Zidesamtinib | Jideytro | none listed | n/a | No | No current entry | 0 |
| Adagrasib | Krazati | none listed | n/a | No | No current entry | 0 |
| Amivantamab | Rybrevant | none listed | n/a | No | No current entry | 0 |
| Atezolizumab and hyaluronidase | Tecentriq | none listed | n/a | No | No current entry | 0 |
| Binimetinib | Mektovi | none listed | n/a | No | No current entry | 1 |
| Datopotamab deruxtecan | Datroway | none listed | n/a | No | No current entry | 0 |
| Encorafenib | Braftovi | none listed | n/a | No | No current entry | 0 |
| Lurbinectedin | Zepzelca | none listed | n/a | No | No current entry | 0 |
| Pembrolizumab | Keytruda | none listed | n/a | No | No current entry | 1 |
| Pralsetinib | Gavreto | none listed | n/a | Yes | No current entry | 0 |
| Sevabertinib | Hyrnuo | none listed | n/a | No | No current entry | 0 |
| Taletrectinib adipate | Ibtrozi | none listed | n/a | No | No current entry | 0 |
| Tepotinib | Tepmetko | none listed | n/a | No | No current entry | 0 |
| Trastuzumab deruxtecan | Enhertu | none listed | n/a | Yes | No current entry | 0 |
| Zongertinib | Hernexeos | none listed | n/a | No | No current entry | 0 |
Source: FDA drug labels (indications) via openFDA; NDC Directory; CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)